Abstract. MicroRNAs (miRs) are a class of small non-coding RNAs that are involved in the regulation of gene expression, and in cancer development and progression. In the present study, miR-320 expression was found to be significantly reduced in glioma tissue in comparison with that in adjacent healthy tissues. In the present study, in vitro analyses demonstrated that overexpression of miR-320 inhibited cell proliferation and metastasis, while antisense miR-320 oligonucleotides enhanced cell proliferation and migration in U251 and SHG-44 glioma cell lines, compared with that in negative control cells. Protein expression of E2F1, a cell-cycle regulator, was negatively regulated by miR-320. Therefore, the present study provides novel insights into the association between miR-320 and glioma development.
Introduction
Glioma arises from glial cells and accounts for 80% of all malignant brain tumors (1) . Although extensive investigations have been performed in order to understand the mechanisms underlying its pathogenesis, the molecular pathways involved in the initiation and progression of glioma remain unclear (1) (2) (3) .
MicroRNAs (miRs), a class of non-coding RNA molecules, are involved in the transcriptional and post-transcriptional regulation of gene expression (4, 5) . Recent investigations have demonstrated that glioma growth is controlled by a number of miRs (6, 7) . miR-16 inhibits glioma cell growth and invasion by suppressing the BCL2 and nuclear factor-κB1/MMP9 signaling pathway (8) . Other investigations have demonstrated that miR-155 overexpression in patients with glioma is an indicator of poor prognosis (9) . Therefore, an investigation into the dysregulated miRs that are involved in the development of glioma may help to elucidate the prognostic value and therapeutic potential of miRs in patients with this disease.
Previous investigations have indicated that miR-320 is involved in the development of a number of types of tumors. For example, miR-320 inhibits cell proliferation and induces apoptosis in breast, prostate and hepatocellular carcinoma (10) (11) (12) (13) . However, until now, the molecular mechanisms underlying the involvement of miR-320 in gliomagenesis remain poorly understood.
Materials and methods
Cell culture and tissue samples. U251 and SHG-44 glioma cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum. Cultures were maintained at 37˚C in a humidified atmosphere with 5% CO 2 . Tumor tissues and adjacent healthy tissues were collected during elective therapeutic surgery (tumor resection) at the Department of Neurosurgery, Tongji Hospital (Shanghai, China) between January and March 2014. All samples were obtained with informed consent and with the approval of the institutional review board of Tongji Hospital.
Analysis of miR expression using TaqMan
® reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA from tissue samples and cell lines was harvested using the miR Isolation kit (Ambion Life Technologies, Carlsbad, CA, USA). Expression of mature miRs was assayed using a TaqMan MiR Assay (Applied Biosystems, Beijing, China) specific for miR-320. Total RNA (5 ng) was reverse transcribed to cDNA using specific stem-loop RT primers (5'-AAA AGC TGG GTT GAG AGG GCGA-3' and a reverse complement primer; Ambion Life Technologies). qPCR was performed MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1 
Bromodeoxyuridine (BrdU) assays.
A cell proliferation enzyme-linked immunosorbent assay (BrdU kit; Beyotime Biotechnology, Nantong, China) was used in order to assess the incorporation of BrdU during DNA synthesis, according to the manufacturer's instructions. Experiments were repeated three times. Absorbance was measured at 450 nm using a Spectra Max 190 ELISA reader (Molecular Devices, Sunnyvale, CA, USA)
Cell migration assays. Cell migration capability was analyzed using Transwell ® migration chambers (Millipore, Hayward, CA, USA) and a ELx800 absorbance reader (BioTek, Winooski, VT, USA) was used to quantify cell migration at 570 nm, according to the manufacturer's instructions.
Western blotting. Cells or tissues were harvested and lysed with ice-cold lysis buffer (50 mM Tris-HCl, pH 6.8; 100 mM 2-ME; 2% w/v SDS and 10% glycerol; Beyotime Biotechnology). Following centrifugation at 20,000 x g for 10 min at 4˚C, proteins in the supernatants were quantified, separated using 10% SDS PAGE and transferred to a nitrocellulose membrane (Amersham Bioscience, Amersham, UK). Non-fat milk (10%) in phosphate-buffered saline was used to block the membranes. Subsequently the membranes were immunoblotted using the following primary antibodies: Rabbit polyclonal anti-E2F1 (1:1,000; cat. no. 3742; Cell Signaling Technology, Inc., Beverley, MA, USA) and mouse monoclonal anti-GAPDH (1:10,000; cat. no. sc-365062; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) at 4˚C for 12 h, followed by horseradish-linked secondary antibodies (1:2,000; cat. nos. 7054 and 7056; Cell Signaling Technology, Inc.) at 25˚C for 2 hr.
Protein expression was detected using a SuperSignal West Pico Chemiluminescent Substrate kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Anti-E2F1 antibodies were purchased from Cell Signaling Technology, Inc.). Protein expression levels were standardized against GAPDH, using the mouse anti-GAPDH antibody.
Luciferase reporter assay. The potential targets of miR-320 were analyzed using miRWalk software (http://www.umm. uni-heidelberg.de/apps/zmf/mirwalk/) (14) . Total cDNA from U251 cells was used to amplify the 3'-untranslated region (UTR) of E2F1. The E2F1 3'-UTR was cloned into an miR expression reporter vector system (pMir-REPORT TM ; Ambion Life Technologies). Mutations were introduced into the potential miR-320 binding sites using the QuikChange site-directed mutagenesis kit (Stratagene, Agilent, San Diego, CA, USA). SHG-44 and U251 cells were transfected with miR-320 mimics or NCs using Lipofectamine 2000 ® . Subsequently, cells were transfected with the pMir-Report vector or with the mutant construct for 36 h. A pRL-SV40 vector (Promega Corporation, Madison, WI, USA) containing the Renilla luciferase gene was used in order to standardize transfection efficiency. Luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega Corporation).
Statistical analysis. Data are expressed as the mean ± standard error of the mean from at least three repeated experiments. Differences between groups were analyzed using Student's t-test. All statistical analyses were conducted using SPPS version 20.0 (IBM, Armonk, NY, USA) P<0.05 was considered to indicate a statistically significant difference.
Results

miR-320 expression was downregulated in patients with
glioma. In order to analyze the association between miR-320 expression and glioma, miR-320 expression was determined using RT-qPCR in 25 pairs of human glioma tissues and adjacent healthy tissues. Expression of miR-320 was significantly decreased in glioma tissues, compared with that of adjacent healthy tissues (Fig. 1) . miR-320 overexpression inhibits cell proliferation. In order to assess the effects of miR-320 on glioma cell growth, miR-320 mimics or NCs were transfected into U251 and SHG-44 cells ( Fig. 2A and B) . In comparison with NC cells, cell numbers and proliferation were significantly lower in U251 and SHG-44 cells lines overexpressing miR-320 mimics (Fig. 2C-F) . Furthermore, miR-320 mimic overexpression significantly inhibited in vitro migration capabilities of the U251 and SHG-44 cell lines compared with that of the NC cells (Fig. 2G-H) .
Inhibition of miR-320 promotes the proliferation of glioma cells.
In order to demonstrate the association between miR-320 expression and glioma cell growth, U251 and SHG-44 cells were transfected with an antisense oligonucleotide against miR-320, which inhibited endogenous miR-320 activity. This resulted in enhanced growth of the antisense-transfected cells compared with that of NC cells (Fig. 3A-D) . In addition, the in vitro migration capability of antisense-transfected cells was significantly higher than that of NC cells (Fig. 3E-F) .
miR-320 directly targets the E2F1 in glioma cells. Using a bioinformatics approach (miRWalk software), a number of putative target genes of miR-320 were identified (data not provided), among which the gene encoding E2F1 harbored a potential miR-320 binding site (Fig. 4A) . Luciferase activity was significantly lower in cells overexpressing miR-320 compared with NC cells following transfection with pMir-REPORT vectors (Fig. 4B) . No significant difference in luciferase activity was observed in mutated U251 and SHG-44 cells (mutation of the conserved miR-320 binding motif) between cells overexpressing miR-320 and NC cells (Fig. 4B) . E2F1 protein expression was lower in cells overexpressing miR-320 mimics compared with that of the NC cells (Fig. 4C-D) . 
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E2F1 protein expression was significantly higher in antisense miR-320-transfected cells compared with that in the NC cells (Fig. 4E-F) , which indicates that E2F1 may be a target of miR-320 in glioma cells. Expression levels of down-stream target genes of E2F1, Cyclin B1 and Cyclin E (13, 15) , were significantly higher in cells overexpressing miR-320 mimics and significantly lower in antisense miR-320-transfected cells compared with those of the NC cells in each case (Fig. 4G-H) . In order to verify the association between miR-320 and E2F1, U251 cells were transfected with lentiviruses containing an E2F1 gene or an empty vector (EV), following transfection with miR-320 mimics (Fig. 5A) . U251 cell proliferation and migration levels were significantly lower following transfection with miR-mimic and the EVs compared with those of cells transfected with miR-320 mimic and E2F1 vectors, and with NC cells transfected with EVs (Fig. 5B-D) . Overall, the results of the present study suggest that the mechanisms underlying the effect of miR-320 on glioma development are associated with the regulation of E2F1.
Discussion
A recent study demonstrated that miR-320 regulates tumor angiogenesis, which is driven by vascular endothelial cells in oral cancer by silencing the expression of neuropilin 1 (16) . Another study demonstrated that miR-320 inhibits osteosarcoma cell proliferation by directly targeting fatty acid synthase (17) . In the present study, miR-320 expression was shown to be lower in glioma tissues compared with that of adjacent healthy tissues. The results suggest that miR-320 overexpression inhibits glioma cell proliferation, metastasis and invasion, compared with that of NC cells and miR-320 antisense-transfected cells. Therefore, in accordance with previous reports, the present study suggests that miR-320 may suppress tumor development and progression.
Computational algorithms have been used to predict multiple genes as potential targets of miR-320 (16, 17) . The results of the present study suggest that miR-320 targets the 3'UTR of E2F1 and is involved in regulating E2F1 expression. E2F1 is a transcription factor involved in the pRb/E2F1 pathway and in the regulation of the G1/S phase (18) . Tumor suppression triggered by pRb has been associated with its ability to inhibit E2F1-responsive promoters (18) . E2F1-responsive promoters were more active in glioma cells than in healthy cells in an investigation by Alonso et al (19) , which suggests that there is more 'free' E2F1 and fewer pRb/E2F1 repressor complexes in glioma cells compared with healthy cells. E2F1 activity is capable of suppressing and promoting tumor development (20) . Although the precise mechanisms are currently unclear, E2F1 activity may be dependent on the nature of associated oncogenic mutations. A cluster of miRs, including miR-106a, miR-138 and miR-329, promoted glioma cell proliferation by targeting E2F1 (21) (22) (23) , which suggests that E2F1 is involved in glioma cell proliferation and that E2F1 expression may be regulated by a number of factors.
In conclusion, the present study demonstrated that miR-320 was downregulated in glioma tissues and could inhibit cell proliferation by targeting E2F1. Since E2F1 has a critical role in cell proliferation, differentiation and apoptosis, further studies are required to establish the role of miR-320 in glioma.
